Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDPH.L Regulatory News (DPH)

  • There is currently no data for DPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Dechra Pharmaceuticals plc

4 Dec 2023 09:16

RNS Number : 5517V
Societe Generale SA
04 December 2023

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Full name of discloser:

SOCIETE GENERALE SA

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor, and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Dechra Pharmaceuticals plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

01/12/2023

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

1p ordinary

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

6,569,274

5.77

8,544

0.01

(2) Cash-settled derivatives:

0

0.00

5,278,730

4.63

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00

0

0.00

TOTAL:

6,569,274

5.77

5,287,274

4.64

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors' and other employee options)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

GBP

1p ordinary

Purchase

10

38.28

1p ordinary

Purchase

22

38.28

1p ordinary

Purchase

37

38.28

1p ordinary

Purchase

44

38.28

1p ordinary

Purchase

68

38.28

1p ordinary

Purchase

192

38.28

1p ordinary

Purchase

200

38.28

1p ordinary

Purchase

219

38.28

1p ordinary

Purchase

219

38.28

1p ordinary

Purchase

371

38.28

1p ordinary

Purchase

439

38.28

1p ordinary

Purchase

439

38.28

1p ordinary

Purchase

439

38.28

1p ordinary

Purchase

439

38.28

1p ordinary

Purchase

439

38.28

1p ordinary

Purchase

6

38.28

1p ordinary

Purchase

10

38.28

1p ordinary

Purchase

47

38.28

1p ordinary

Purchase

59

38.28

1p ordinary

Purchase

62

38.28

1p ordinary

Purchase

70

38.28

1p ordinary

Purchase

78

38.28

1p ordinary

Purchase

91

38.26

1p ordinary

Purchase

94

38.28

1p ordinary

Purchase

111

38.28

1p ordinary

Purchase

117

38.26

1p ordinary

Purchase

220

38.28

1p ordinary

Purchase

282

38.28

1p ordinary

Purchase

600

38.28

1p ordinary

Purchase

621

38.28

1p ordinary

Purchase

14

38.28

1p ordinary

Purchase

43

38.28

1p ordinary

Purchase

60

38.26

1p ordinary

Purchase

77

38.28

1p ordinary

Purchase

94

38.28

1p ordinary

Purchase

97

38.16

1p ordinary

Purchase

113

38.16

1p ordinary

Purchase

149

38.26

1p ordinary

Purchase

945

38.26

1p ordinary

Purchase

2,880

38.26

1p ordinary

Sale

113

38.26

1p ordinary

Sale

43

38.28

1p ordinary

Sale

43

38.28

1p ordinary

Sale

43

38.28

1p ordinary

Sale

43

38.28

1p ordinary

Sale

371

38.28

1p ordinary

Sale

403

38.28

1p ordinary

Sale

439

38.28

1p ordinary

Sale

439

38.28

1p ordinary

Sale

523

38.28

1p ordinary

Sale

1,382

38.28

1p ordinary

Sale

1

38.28

1p ordinary

Sale

1

38.28

1p ordinary

Sale

1

38.28

1p ordinary

Sale

2

38.28

1p ordinary

Sale

14

38.28

1p ordinary

Sale

20

38.28

1p ordinary

Sale

24

38.28

1p ordinary

Sale

26

38.28

1p ordinary

Sale

31

38.28

1p ordinary

Sale

51

38.28

1p ordinary

Sale

63

38.28

1p ordinary

Sale

87

38.28

1p ordinary

Sale

87

38.28

1p ordinary

Sale

87

38.28

1p ordinary

Sale

87

38.28

1p ordinary

Sale

191

38.28

1p ordinary

Sale

242

38.28

1p ordinary

Sale

243

38.28

1p ordinary

Sale

272

38.28

1p ordinary

Sale

332

38.28

1p ordinary

Sale

347

38.28

1p ordinary

Sale

504

38.28

1p ordinary

Sale

805

38.28

1p ordinary

Sale

1,000

38.28

1p ordinary

Sale

1,104

38.28

1p ordinary

Sale

1,390

38.28

1p ordinary

Sale

1,460

38.28

1p ordinary

Sale

3,223

38.28

1p ordinary

Sale

8,401

38.28

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

GBP

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

04/12/2023

Contact name:

Paul Jenkins

Telephone number:

+44 20 7676 6969

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RETGCBDDSBGDGXS
Date   Source Headline
16th Jan 20244:54 pmRNSHolding(s) in Company
16th Jan 20243:29 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Jan 20242:43 pmRNSHolding(s) in Company
16th Jan 20241:25 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Jan 20241:15 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Jan 20241:02 pmGNWForm 8.3 - Dechra Pharmaceuticals PLC
16th Jan 202412:50 pmRNSForm 8.5 (EPT/RI)-Replacement of Dechra
16th Jan 202412:44 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Jan 202412:04 pmRNSHolding(s) in Company
16th Jan 202410:15 amRNSScheme of Arrangement becomes Effective
16th Jan 202410:11 amRNSForm 8.5 (EPT/NON-RI) - Dechra Pharmaceuticals PLC
16th Jan 202410:11 amRNSForm 8.5 (EPT/RI)
16th Jan 20249:20 amRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Jan 20249:04 amRNSForm 8.5 (EPT/RI)-Dechra Pharmaceuticals plc
16th Jan 20249:00 amRNSHolding(s) in Company
16th Jan 20248:12 amRNSForm 8.5 (EPT/NON-RI) Dechra Pharmaceuticals Plc
16th Jan 20247:39 amGNWForm 8.5 (EPT/RI) - Dechra Pharmaceuticals plc
16th Jan 20247:30 amRNSSuspension - Dechra Pharmaceuticals PLC
15th Jan 20244:51 pmRNSDirector/PDMR Shareholding
15th Jan 20243:51 pmRNSHolding(s) in Company
15th Jan 20243:30 pmGNWForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 20243:20 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 20243:03 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 20241:57 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 20241:46 pmEQSForm 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
15th Jan 202412:35 pmGNWForm 8.3 - Dechra Pharmaceuticals PLC
15th Jan 202412:05 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 202411:51 amRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 202411:25 amRNSForm 8.5 (EPT/NON-RI) Dechra Pharmaceuticals Plc
15th Jan 20249:58 amRNSForm 8.5 (EPT/NON-RI)
15th Jan 20249:58 amRNSForm 8.5 (EPT/RI)
15th Jan 20249:31 amRNSForm 8.5 (EPT/RI)-Dechra Pharmaceuticals plc
15th Jan 20249:13 amRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 20247:29 amGNWForm 8.5 (EPT/RI) - Dechra Pharmaceuticals plc
12th Jan 20244:02 pmRNSCourt sanction of Scheme of Arrangement
12th Jan 20243:30 pmGNWForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 20243:20 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 20243:07 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 20242:42 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 20242:30 pmRNSHolding(s) in Company
12th Jan 20241:38 pmEQSForm 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
12th Jan 20241:24 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 202412:03 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 202410:39 amGNWForm 8.3 - Dechra Pharmaceuticals PLC
12th Jan 202410:39 amRNSForm 8.5 (EPT/RI)
12th Jan 202410:36 amRNSForm 8.5 (EPT/NON-RI)
12th Jan 202410:35 amRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 20249:34 amRNSHolding(s) in Company
12th Jan 20249:22 amRNSForm 8.5 (EPT/RI)-Dechra Pharmaceuticals plc
12th Jan 20248:09 amGNWForm 8.5 (EPT/RI) - Dechra Pharmaceuticals plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.